BENZALKONIUM CHLORIDE 0.13% (DK12 Liquid Hand Oatmeal)
What to know about BENZALKONIUM CHLORIDE 0.13% — also sold as DK12 Liquid Hand Oatmeal: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
BENZALKONIUM CHLORIDE 0.13% (brand names: DK12 Liquid Hand Oatmeal) is classified as Minimal risk by AllMeds. FDA approved in the United States. Topical antiseptic with no workplace safety concerns.
Key Takeaways
- Risk level: Minimal (0 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | Unscheduled | Not PBS listed |
| United States (FDA) | Rx only | FDA approved |
Risk Profile
Topical antiseptic with no workplace safety concerns.
How BENZALKONIUM CHLORIDE 0.13% is regulated
BENZALKONIUM CHLORIDE 0.13% is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Australia TGA / PBS / State Schemes
Classified as Unscheduled under the Therapeutic Goods Administration (TGA).
United States FDA / CDC / State WC
FDA approved for use in the United States.
Check this medication against your full medication list
Run a full risk assessment including BENZALKONIUM CHLORIDE 0.13% interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.